Mefilab-Spas Tablet is a combination medication containing Dicyclomine 10 mg and Mefenamic Acid 250 mg, designed for the management of gastrointestinal spasms and associated pain. Dicyclomine is an anticholinergic agent that acts by inhibiting muscarinic receptors in the smooth muscles of the gastrointestinal tract, thereby reducing muscle spasms and cramps. Mefenamic Acid is a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, leading to decreased prostaglandin synthesis. This dual-action formulation is indicated for the relief of abdominal pain and discomfort associated with irritable bowel syndrome, dysmenorrhea, and other conditions characterized by smooth muscle spasms and inflammation. Mefilab-Spas Tablet should be used under medical supervision, particularly in patients with a history of gastrointestinal ulcers, bleeding disorders, or hypersensitivity to NSAIDs or anticholinergic agents. Common side effects may include dry mouth, dizziness, nausea, or mild gastrointestinal upset. It is contraindicated in patients with obstructive gastrointestinal conditions, severe renal or hepatic impairment, and pregnancy. Dosage should be individualized based on clinical response, and patients are advised to adhere strictly to prescribed instructions to minimize adverse effects and ensure therapeutic efficacy.